The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Multiple myeloma is a complex, heterogeneous plasma cell malignancy typically diagnosed in older adults.
• Risk stratification tools have evolved from the Durie and Salmon system to the International Staging System (ISS), revised as R-ISS and R2-ISS.
• Therapeutic advancements include immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies, significantly altering treatment paradigms.

Purpose of the Study:

• To review the evolution of risk stratification in multiple myeloma.
• To provide an overview of current and emerging therapeutic strategies.
• To highlight the challenges and unmet needs in multiple myeloma treatment.

Main Methods:

• Literature review of multiple myeloma staging systems and therapeutic advancements.
• Analysis of the role of immune system dysfunction in multiple myeloma.
• Discussion of novel T cell-directed therapies, including CAR T cells and bispecific antibodies.

Main Results:

• Risk stratification has progressively improved prognosis prediction and treatment guidance.
• Novel therapies, particularly T cell-based approaches targeting BCMA or GPRC5D, show promise for relapsed/refractory disease.
• Despite progress, multiple myeloma remains incurable, with extramedullary disease and plasma cell leukemia representing significant unmet needs.

Conclusions:

• Continuous refinement of risk stratification is crucial for personalized multiple myeloma management.
• T cell-directed immunotherapies represent a major advancement, offering new hope for difficult-to-treat patients.
• Further research is essential to overcome treatment resistance and achieve a cure for multiple myeloma.